skip to Main Content

Researchers Hope to Confirm ‘Remarkable Results’ of Novel Drug Combination for Advanced Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Researchers at Stony Brook University’s Renaissance School of Medicine have developed an enzyme-targeting drug that could prolong survival for patients with metastatic pancreatic cancer.

“Pancreatic cancer is a lethal disease for which incidence matches closely to all patient mortality,” Minsig Choi, MD, medical oncologist on the Stony Brook University Cancer Center gastroenterology oncology team at Renaissance School of Medicine, said in an interview with Healio. “Overall survival for advanced pancreatic cancer is 6 to 12 months for treated patients and less than 3 months for untreated patients.” Read more . . . 

Back To Top